JP2007183187A - SPECIFIC QUANTIFICATION METHOD OF beta-CASEIN PHOSPHOPETIDE (beta-CPP) USING IMMUNOLOGICAL TECHNIQUE - Google Patents
SPECIFIC QUANTIFICATION METHOD OF beta-CASEIN PHOSPHOPETIDE (beta-CPP) USING IMMUNOLOGICAL TECHNIQUE Download PDFInfo
- Publication number
- JP2007183187A JP2007183187A JP2006001851A JP2006001851A JP2007183187A JP 2007183187 A JP2007183187 A JP 2007183187A JP 2006001851 A JP2006001851 A JP 2006001851A JP 2006001851 A JP2006001851 A JP 2006001851A JP 2007183187 A JP2007183187 A JP 2007183187A
- Authority
- JP
- Japan
- Prior art keywords
- cpp
- sample
- casein
- mab
- calibration curve
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Peptides Or Proteins (AREA)
Abstract
Description
本発明は、カゼインホスホペプチドの内、特にβ−カゼインホスホペプチド(以下「β-CPP」と称する)を特異的に認識するモノクローナル抗体を用いた免疫学的測定法に関する。 The present invention relates to an immunoassay using a monoclonal antibody that specifically recognizes β-casein phosphopeptide (hereinafter referred to as “β-CPP”) among casein phosphopeptides.
ミルクタンパク質であるカゼインを消化酵素によって分解するとオピオイドペプチドをはじめとする多くの生理活性ペプチドが生ずることが知られている。カゼインホスホペプチド(以下「CPP」と称する)はin vitro、in vivoでαs1-カゼイン、αs2-カゼイン、及びβ-カゼインが加水分解されて生成するリン酸化ペプチドである。構造的特長として、3つの連続したリン酸化セリンに続く2つのグルタミン酸を共通のモチーフとして持っている。これらのモチーフは、カルシウム、鉄、亜鉛等のミネラルと相互をして生体の利用を高める作用が知られている(非特許文献1)。さらに、CPPと非結晶リン酸カルシウム(Casein Phosphopeptide-Amorphous Calcium Phosphate ;CPP-ACP) 複合体は歯の再石灰化能を有することが科学的に証明され(非特許文献2、特許文献1)、ガムへ添加した製品は再石灰化を訴求した特定保健用食品となっている。
CPPの同定は陰イオン交換HPLCや逆相HPLCで分離した後、マス分析を併用して行われている(非特許文献3, 4)。しかし、ピークの帰属等を正確に決めるためには時間を要し、作業操作が煩雑で高価な機器も必要となる。さらに、乳製品に添加するような場合、その配合量の定量は、類似する物質が共存するため、通常の免疫学的方法もそのままでは使えない。一部チーズ熟成期間における特定のペプチドの消長について、抗ペプチドポリクローナル抗体を用いて定量が試みられている(非特許文献5)。しかしながら、厳密に特異性を担保するためには、一般的にはポリクローナル抗体よりもモノクローナル抗体の方が望ましいと考えられる。さらに、該報告では前処理として、凍結乾燥、脱脂を行った後測定をしているが、乳由来素材を乳製品に添加する様な場合、内在する類似物を効率的に除去する調製法の工夫も必要である。
また、CPPはpHやカルシウム及びリン酸塩濃度により様々なリン酸カルシウム相を取ることが知られている(特許文献1)。その為、現状ではCPP-ACP等のCPP複合体をそのままの形で直接定量することは容易でない。さらに、CPPとリン酸カルシウムの複合体をゲル濾過HPLCにて分離している報告があるが(非特許文献6)、定量的な手段としての利用には十分とはいえない。加えて、CPP-ACPは特にELISAプレートへのコーティング効率が極めて低く、通常の間接ELISA法が適用できない。
Identification of CPP is performed by using mass analysis after separation by anion exchange HPLC or reverse phase HPLC (
CPP is known to take various calcium phosphate phases depending on pH, calcium and phosphate concentrations (Patent Document 1). Therefore, at present, it is not easy to directly quantify CPP complexes such as CPP-ACP as they are. Furthermore, although there is a report that a complex of CPP and calcium phosphate is separated by gel filtration HPLC (Non-patent Document 6), it is not sufficient for use as a quantitative means. In addition, CPP-ACP has a particularly low coating efficiency on ELISA plates, and the usual indirect ELISA method cannot be applied.
乳製品等食品中に添加されたCPP及びCPP複合体中のβ-CPPを特異的に簡便かつ精度よく測定する方法を提供することを課題とする。さらに、食品成分の分析において、迅速で、経済的、正確かつ高感度、そしてルーチンに利用できる社会的ニーズに対して、免疫学的なアッセイ法を提供することである。 It is an object of the present invention to provide a method for specifically and simply and accurately measuring CPP added to foods such as dairy products and β-CPP in CPP complexes. Furthermore, it is to provide an immunological assay for the social needs that are rapid, economical, accurate and sensitive and routinely available in the analysis of food ingredients.
本発明者等は、鋭意研究した結果、β-CPPに対するモノクローナル抗体(mAb 1A5)による免疫学的方法と測定系に適したサンプル調製法を組み合わせることにより、食品中のβ-CPPを簡便かつ特異的に精度よく測定することが可能であることを見出し、本発明を完成させた。
すなわち本発明は、
[1] 配列番号:1記載のリン酸化ペプチドに対するモノクローナル抗体(mAb 1A5)を用いた免疫学的測定法によるβ−カゼインホスホペプチド及び/又はβ−カゼインホスホペプチド複合体の定量法、
[2] 以下の工程からなる免疫学的測定法による前記[1]記載の定量法、
(1)試料に酸を加え、タンパク質を変性・除去する工程
(2)固相抽出により、酸を除去する工程
(3)固相から溶出した精製試料を配列番号:1記載のリン酸化ペプチドに対するモノクローナル抗体(mAb 1A5)を用いて免疫学的測定を行う。
[3] 乳製品中のβ−カゼインホスホペプチド及び/又はβ−カゼインホスホペプチド複合体を定量することを特徴とする前記[1]又は[2]記載の定量法、
からなる。
As a result of earnest research, the present inventors have combined β-CPP in food with a simple and specific method by combining an immunological method with a monoclonal antibody against mAb (mAb 1A5) and a sample preparation method suitable for the measurement system. And the present invention was completed.
That is, the present invention
[1] Quantitative determination of β-casein phosphopeptide and / or β-casein phosphopeptide complex by immunoassay using a monoclonal antibody (mAb 1A5) against the phosphorylated peptide of SEQ ID NO: 1,
[2] The quantification method according to the above [1] by an immunological assay comprising the following steps:
(1) Step of adding acid to sample and denaturing / removing protein (2) Step of removing acid by solid phase extraction (3) Purified sample eluted from solid phase for phosphorylated peptide of SEQ ID NO: 1 Immunological measurements are performed using a monoclonal antibody (mAb 1A5).
[3] The method according to [1] or [2], wherein the β-casein phosphopeptide and / or β-casein phosphopeptide complex in the dairy product is quantified,
Consists of.
本発明の方法を用いれば、製品中に類似する物質が共存している様な場合でも、測定対象物質を特異的に定量することが出来る。さらに、実施に当たって、高価な測定機器や特殊な技能・知識も必要とせず、操作性も簡便である利点がある。 By using the method of the present invention, the substance to be measured can be specifically quantified even when similar substances coexist in the product. Furthermore, there is an advantage in that it does not require expensive measuring equipment, special skills / knowledge, and is easy to operate.
以下、本発明を詳細に説明する。
本発明で用いるCPPは、カゼインをトリプシンで加水分解して得られるカゼインホスホペプチドを指し、製造法については、特開昭56−123921号公報、特開昭59−159792号公報、特開昭59−159793号公報、特開平2−257854号公報、等が例示できる。
カゼインホスホペプチド複合体とは、カゼイントリプシン分解物とカルシウム、リン酸等の無機塩との複合体を形成させたもの及びその誘導体を指し、特表2002-500626号公報が例示できる。
本発明で用いる抗体は、配列番号:1記載のβ−カゼインの部分配列に対するモノクローナル抗体(第49回日本栄養・食糧学会大会 講演要旨集p126 3A-3aに従って作製、以下mAb 1A5という)が例示できる。
Hereinafter, the present invention will be described in detail.
CPP used in the present invention refers to a casein phosphopeptide obtained by hydrolyzing casein with trypsin, and the production method is described in JP-A-56-123922, JP-A-59-159792, JP-A-59. -159793, JP-A-2-257854, and the like.
The casein phosphopeptide complex refers to a complex formed of a casein trypsin degradation product and an inorganic salt such as calcium and phosphoric acid, and derivatives thereof, and can be exemplified by JP-T 2002-500626.
The antibody used in the present invention can be exemplified by a monoclonal antibody against a partial sequence of β-casein described in SEQ ID NO: 1 (produced according to the 49th Annual Meeting of the Japan Society of Nutrition and Food Science p126 3A-3a, hereinafter referred to as mAb 1A5). .
CPP及びCPP複合体を配合した乳製品サンプルは、トリクロロ酢酸等の酸処理の後、遠心操作により、内在するカゼイン、乳清等に由来する高分子タンパク質を変性、除去する。次に、固相抽出により酸を除くと共に固相マトリックスに結合したCPP含有画分を溶出、乾固する。CPP及びCPP複合体(標準品)を製品と同等組成の溶液に溶解して検量線サンプルを調製し、乳製品サンプルと同一条件で前処理することにより、回収率のファクターを相殺出来る。製品と組成が同等で測定対象物を含まないもの(プラセボ)が利用できない場合は、製品中に既知量のCPP及びCPP複合体を添加して作成した検量線から間接的に算出することも可能である。さらにプラセボ中に存在するCPP及びCPP複合体含量を求めるには、検量線サンプルをPBS、生理食塩水など適当な溶媒で調製して求めた検量線が利用できる。乳製品としては、生乳、加工乳、チーズ、ヨーグルト、アイスクリーム等に応用出来る。 A dairy product sample containing CPP and CPP complex is subjected to acid treatment such as trichloroacetic acid, and then denatures and removes macromolecular proteins derived from casein, whey and the like by centrifugation. Next, the CPP-containing fraction that removes the acid by solid phase extraction and is bound to the solid matrix is eluted and dried. A calibration curve sample is prepared by dissolving CPP and CPP complex (standard product) in a solution having the same composition as the product, and pretreatment under the same conditions as the dairy product sample can offset the recovery factor. If a product that has the same composition as the product and does not contain the measurement target (placebo) cannot be used, it can be indirectly calculated from a calibration curve created by adding a known amount of CPP and CPP complex to the product. It is. Furthermore, in order to determine the CPP and CPP complex content present in the placebo, a calibration curve obtained by preparing a calibration curve sample with an appropriate solvent such as PBS or physiological saline can be used. As dairy products, it can be applied to raw milk, processed milk, cheese, yogurt, ice cream and the like.
免疫学的な定量は、競合Enzyme-linked immunosorbent assay (ELISA)によった(Hornbeck P. Enzyme-Linked Immunosorbent Assays. In Current Protocols in Immunology; Coligan, J.E., Kruisbeek, A.M., Margulies, D.H., Shevach, E.M., Strober, W., Ed.; John Wiley & Sons, Inc, 1991; 2.1.1-2.1.22.)。
CPP及びCPP複合体を配合した前処理済みの乳製品サンプル或いは検量線サンプルをモノクローナル抗体と反応させる(プレインキュベーション)。測定用96ウエルプレートは、CPPIII(明治製菓)でコーティング(固相化)した後、後に行う反応の非特異的吸着を防ぐためにウシ血清アルブミン(BSA)でブロッキングする。ブロッキング済みの測定用プレートにプレインキュベーションした乳製品サンプル或いは検量線サンプルとモノクローナル抗体の混合物を移す。乳製品サンプル或いは検量線サンプル中のβ-CPPはモノクローナル抗体との結合において、固相化したCPPIII中のβ-CPPと競合する。続いて、未反応物を洗浄、除去し、固相化したβ-CPPと結合したモノクローナル抗体を酵素標識した2次抗体による呈色反応により測定する。検量線サンプルから求めた近似曲線から乳製品サンプル中のCPP及びCPP複合体含量を求める。検量線サンプルは既知量のCPP及びCPP複合体を添加して調製するので、製品中に含まれるCPP及びCPP複合体量が求められる。さらに、製品中に含まれるβ-CPP量も、精製したβ-CPPを標準物質として、CPP及びCPP複合体原体について上述の競合ELISA法を適用することで算出できる。
Immunological quantification was performed by competitive Enzyme-linked immunosorbent assay (ELISA) (Hornbeck P. Enzyme-Linked Immunosorbent Assays. In Current Protocols in Immunology; Coligan, JE, Kruisbeek, AM, Margulies, DH, Shevach, EM Strober, W., Ed .; John Wiley & Sons, Inc, 1991; 2.1.1-2.1.22.).
A pretreated dairy sample or calibration curve sample containing CPP and CPP complex is reacted with a monoclonal antibody (preincubation). The 96-well plate for measurement is coated (solid phase) with CPPIII (Meiji Seika) and then blocked with bovine serum albumin (BSA) to prevent non-specific adsorption of the subsequent reaction. Transfer the pre-incubated dairy sample or calibration curve sample and monoclonal antibody mixture to the blocked assay plate. Β-CPP in dairy samples or calibration curve samples competes with β-CPP in immobilized CPPIII for binding to monoclonal antibodies. Subsequently, unreacted substances are washed and removed, and measurement is performed by a color reaction using a secondary antibody that is enzyme-labeled with a monoclonal antibody bound to β-CPP immobilized on a solid phase. CPP and CPP complex content in the dairy product sample is obtained from the approximate curve obtained from the calibration curve sample. Since the calibration curve sample is prepared by adding a known amount of CPP and CPP complex, the amount of CPP and CPP complex contained in the product is determined. Furthermore, the amount of β-CPP contained in the product can also be calculated by applying the above-mentioned competitive ELISA method to CPP and CPP complex bulk material using purified β-CPP as a standard substance.
以下、本発明を実施例を挙げて説明するが、本発明はこれにより限定されるものではない。 EXAMPLES Hereinafter, although an Example is given and this invention is demonstrated, this invention is not limited by this.
[実施例1]プロセスチーズ及びプロセスチーズに添加したCPP含量の測定
試験原料としてニュージーランドゴーダプロセスチーズ及び2% CPP配合ニュージーランドゴーダプロセスチーズを用いた。乳鉢中で各チーズに蒸留水を加えて10%(w/v)の均一な水溶液を調製した。さらに、得られた10%(w/v) ニュージーランドゴーダプロセスチーズ水溶液にCPPを2mg/mlになるように添加したものも含め、以下の3種の乳製品サンプルを調製した。
1) ニュージーランドゴーダプロセスチーズ10%溶液
2) 2% CPP配合ニュージーランドゴーダプロセスチーズ10%溶液(CPP: 2mg/ml)
3) CPP(2mg/ml)添加10%ニュージーランドゴーダプロセスチーズ
サンプル前処理は以下に述べる手順で行った。
乳製品サンプル0.3 ml をプラスチックチューブに取り、ボルテックスミキサーで攪拌しながら15%トリクロロ酢酸(TCA) 1.2 ml、続いてPBS 1.5 mlを加え、酸変性したカゼイン等の高分子タンパク質を遠心除去(17000 x g、6min、4℃)した。回収した上清1.2ml に等量のPBS 1.2mlを添加したものの内2mlをあらかじめ100%メタノール2ml、HPLC用蒸留水(0.1%TFA含有)2mlで平衡化した固相抽出用カラム(Waters OASISTM HLB1cc (30mg))にアプライした。カラム中のTCAや非吸着物を蒸留水(0.1% TFA含有) 2ml、5% メタノール(0.1% TFA含有) 2mlで順次洗浄除去した後、50%アセトニトリル(0.1% TFA含有) 2mlにてCPP含有画分を溶出した。得られたCPP含有画分は遠心濃縮機により乾固した。なお、検量線サンプルはCPPIII(標準物質)をリン酸緩衝溶液(PBS)に溶解した。
競合ELISA法は以下に述べる手順で行った。
前処理済みの乳製品サンプルをPBS 0.5mlに溶解し検体原液とした。全ての検体原液をPBSでさらに10倍希釈した。検量線サンプルはCPPIII(標準物質)をPBSで溶解・希釈し、6.25-100μg/mlに調製した。乳製品サンプル及び検量線サンプルを2%BSA/PBSで希釈したmAb 1A5(2μg/ml)と1:1 (50μl:50μl)の量比でU底96ウエルプレート(FALCON #351177)中でプレインキュベーション(37℃、1.5時間)した。測定用96ウエルプレート(Nunc MaxiSorp)は、PBSに溶解したCPPIII (50μg/ml)を100μl/wellで37℃、2時間以上コーティングした後、1%BSA/PBSで37℃1時間ブロッキングした。ブロッキング済みの測定用プレートにプレインキュベーションした検体とmAb 1A5の反応物を50μl/well移し、37℃で1時間反応した。続いて、競合未反応物を洗浄液により除去し、プレート上にコートしたCPPIII中のβ-CPPと結合したmAb 1A5を検出するために、1%BSA/PBSで6000倍に希釈した2次抗体(ペルオキシダーゼ標識ウサギ抗マウス免疫グロブリン抗体(Rockland社))を100μl/well加え、37℃で1時間インキュベーションした。次に、未反応の2次抗体を洗浄液により除去した後、基質発色液 (DAKOTM TMB+SUBSTRATE-CHROMOGEN)を100μl/well分注した。室温で5分間呈色反応を行った後、1Nの硫酸水溶液を100μl/well添加して反応を停止し、プレートリーダを用いて吸光度 (OD 450 nm)を測定した。検量線サンプルの各CPP濃度と対応する吸光度をそれぞれx(対数)、y軸にプロットして作成した検量線より乳製品サンプル中のCPP量を算出した。検量線は測定毎に作成し、乳製品サンプルと同一のプレートで測定したデータを使用した。
CPP濃度を公比2で6.25-100μg/mlに調製した検量線サンプルについて、競合ELISA法を実施して得られた検量線を図1に示した。
次に検量線から得られた近似関数に各チーズサンプルの吸光度を当てはめ、希釈倍率を乗じてCPP配合量を求めた(表1)。
[Example 1] Measurement of process cheese and CPP content added to process cheese New Zealand Gouda Process Cheese and New Zealand Gouda Process Cheese with 2% CPP were used as test materials. Distilled water was added to each cheese in a mortar to prepare a 10% (w / v) uniform aqueous solution. Furthermore, the following three dairy product samples were prepared, including those obtained by adding CPP to the obtained 10% (w / v) New Zealand Gouda processed cheese aqueous solution at 2 mg / ml.
1) New Zealand
2) New Zealand
3) 10% New Zealand Gouda Process Cheese with CPP (2mg / ml) Sample pre-treatment was performed according to the procedure described below.
Take 0.3 ml of dairy sample in a plastic tube, add 1.2 ml of 15% trichloroacetic acid (TCA) and then 1.5 ml of PBS while stirring with a vortex mixer, and centrifuge to remove acid-denatured polymer proteins such as casein (17000
The competitive ELISA method was performed according to the procedure described below.
A pretreated dairy product sample was dissolved in 0.5 ml of PBS to prepare a sample stock solution. All sample stock solutions were further diluted 10-fold with PBS. The calibration curve sample was prepared by dissolving and diluting CPPIII (standard substance) with PBS to 6.25-100 μg / ml. Preincubation of dairy samples and calibration curve samples in U-bottom 96-well plates (FALCON # 351177) at a ratio of 1: 1 (50 μl: 50 μl) to mAb 1A5 (2 μg / ml) diluted in 2% BSA / PBS (37 ° C, 1.5 hours). A 96-well plate (Nunc MaxiSorp) for measurement was coated with CPPIII (50 μg / ml) dissolved in PBS at 100 μl / well at 37 ° C. for 2 hours or more, and then blocked with 1% BSA / PBS at 37 ° C. for 1 hour. The sample pre-incubated on the blocking measurement plate and the reaction product of mAb 1A5 were transferred at 50 μl / well and reacted at 37 ° C. for 1 hour. Subsequently, a secondary antibody (6000 times diluted with 1% BSA / PBS) was detected in order to detect mAb 1A5 bound to β-CPP in CPPIII coated on the plate by removing the unreacted competitor with a washing solution. 100 μl / well of peroxidase-labeled rabbit anti-mouse immunoglobulin antibody (Rockland) was added and incubated at 37 ° C. for 1 hour. Next, the unreacted secondary antibody was removed by a washing solution, and then a substrate coloring solution (DAKO ™ TMB + SUBSTRATE-CHROMOGEN) was dispensed at 100 μl / well. After a color reaction at room temperature for 5 minutes, 100 μl / well of 1N sulfuric acid aqueous solution was added to stop the reaction, and absorbance (
A calibration curve obtained by carrying out the competitive ELISA method for a calibration curve sample prepared with a CPP concentration of 6.25-100 μg / ml at a common ratio of 2 is shown in FIG.
Next, the absorbance of each cheese sample was applied to the approximate function obtained from the calibration curve and multiplied by the dilution factor to obtain the amount of CPP blended (Table 1).
本法は酸処理、固相抽出からなる前処理とβ-CPPに特異的なモノクローナル抗体を用いた競合ELISA法を組み合わせることにより、チーズの熟成過程で生じた多種類のペプチド中から、CPP配合量を特異的に定量することを可能にした。 This method combines a pretreatment consisting of acid treatment and solid-phase extraction with a competitive ELISA method using a monoclonal antibody specific for β-CPP. The amount could be specifically quantified.
[実施例2]モノクローナル抗体(mAb 1A5)のエピトープ領域の検討
化学合成したβ-CPPを構成するペプチド1から16残基(β-CPP(f1-16))、ペプチド20から25残基(β-CPP (f20-25))及びβ-CPP(f1-25)とmAb 1A5との反応性を競合ELISA法により調べた(図2)。
mAb 1A5はβ-CPP(f1-25)とは強く反応するが、β-CPP(f1-16)及びβ-CPP (f20-25)とは反応しなかったことから、エピトープはペプチド17から19残基のリン酸化セリンクラスターを含む領域であることが示唆された。
[Example 2] Examination of epitope region of monoclonal antibody (mAb 1A5)
mAb 1A5 reacts strongly with β-CPP (f1-25) but not with β-CPP (f1-16) and β-CPP (f20-25), so the epitope is from peptide 17 to 19 It was suggested that the region contains a phosphorylated serine cluster of residues.
[実施例3] セリン残基の脱リン酸化がモノクローナル抗体(mAb 1A5)反応性に及ぼす影響
セリン残基のリン酸化が抗体との反応に重要であることを確認するために、CPPを0.2-0.6N のNaOHで37℃、3 時間脱リン酸化処理した(B. Jiang and Y. Mine (2000). Preparation of novel functional oligophosphopeptides from hen egg yolk phosvitin. J. Agric. Food. Chem. 48, 990-994.)。続いて、塩酸で中和した後、固相抽出により遊離したリン酸基を除き、脱リン酸化されたCPP含有画分を回収した。対照群はNaOH処理開始後直ちに中和して脱リン酸化反応を止めた。CPPに含まれるP量の測定はAmesの方法を用いた(B. N. Ames (1966) Assay of Inorganic Phosphate, Total Phosphate. Methods in Enzymology VIII, pp.115-118.)。NaOHの処理濃度に比例してCPP中のP量は減少したが(図3)、ペプチド含量には影響しなかった(図4)。mAb 1A5を用いた競合ELISA法で測定したNaOH処理サンプル中のCPP含量は、脱リン酸化が進むに比例して低下した(図5)。以上の結果は、mAb 1A5はCPPの特にリン酸化セリン残基配列を含む領域を認識していることを支持している。
Example 3 Effect of Serine Residue Dephosphorylation on Monoclonal Antibody (mAb 1A5) Reactivity In order to confirm that serine residue phosphorylation is important for the reaction with an antibody, CPP 0.2- Dephosphorylated with 0.6N NaOH at 37 ° C for 3 hours (B. Jiang and Y. Mine (2000). Preparation of novel functional oligophosphopeptides from hen egg yolk phosvitin. J. Agric. Food. Chem. 48, 990- 994.). Subsequently, after neutralizing with hydrochloric acid, the phosphate group released by solid phase extraction was removed, and the dephosphorylated CPP-containing fraction was recovered. The control group neutralized immediately after the start of NaOH treatment to stop the dephosphorylation reaction. The Ames method was used to measure the amount of P contained in CPP (BN Ames (1966) Assay of Inorganic Phosphate, Total Phosphate. Methods in Enzymology VIII, pp. 115-118). Although the amount of P in the CPP decreased in proportion to the treatment concentration of NaOH (Fig. 3), it did not affect the peptide content (Fig. 4). The CPP content in the NaOH-treated sample measured by competitive ELISA using mAb 1A5 decreased in proportion to the progress of dephosphorylation (FIG. 5). The above results support that mAb 1A5 recognizes a region containing CPP, particularly a phosphorylated serine residue sequence.
[実施例4]モノクローナル抗体(mAb 1A5)反応特異性
ウシカゼインをトリプシン分解すると4種の主要なリン酸化ペプチドが生ずる(表2)。
[Example 4] Specificity of monoclonal antibody (mAb 1A5) reaction Trypsin digestion of bovine casein yields four major phosphorylated peptides (Table 2).
ウシα及びβカゼインをトリプシン分解し、リン酸化ペプチド調製した後、HPLCにより4種のリン酸化ペプチドを精製した(E.C. Reynolds, P. F. Riley and N.J. Adamson (1994). A selective precipitation purification procedure for multiple phosphoseryl-containing peptides and methods for their identification. Anal. Biochem. 217, 277- 284.)。そして、mAb 1A5のペプチド特異性を競合ELISA法により調べた(図6)。
図6に示したように、ウシカゼインをトリプシン分解して生じる4種の主要リン酸化ペプチドの内、今回構築した競合ELISA測定系でmAb 1A5はβ-CPP特異的な反応性を示した。
Bovine α and β caseins were trypsinized to prepare phosphorylated peptides, and then four types of phosphorylated peptides were purified by HPLC (EC Reynolds, PF Riley and NJ Adamson (1994). A selective precipitation purification procedure for multiple phosphoseryl- containing peptides and methods for their identification. Anal. Biochem. 217, 277-284.). The peptide specificity of mAb 1A5 was examined by competitive ELISA (FIG. 6).
As shown in FIG. 6, among the four major phosphorylated peptides generated by trypsin digestion of bovine casein, mAb 1A5 showed β-CPP-specific reactivity in the competitive ELISA assay system constructed this time.
[実施例5]乳製品(試製品)に配合したCPP-ACP含量の測定
検量線サンプルとして試製に用いたCPP-ACP原体(Cadbury Schweppes社)を1g秤量し、蒸留水で100mlのメスフラスコに溶解した後(10mg/ml)、2.5mlずつチューブに分注し、遠心濃縮機により乾固した(25mg/tube)。続いて、CPP-ACP原体25mgに牛乳5mlを加えて十分に溶解した後(5mg/ml)、最終濃度が1、2及び3mg/mlになるように牛乳で段階希釈した。CPP-ACP無添加の牛乳中のCPP-ACP濃度は 0mg/mlとした。
サンプル調製法は以下に述べる手順で行った。
乳製品サンプル0.3 ml をプラスチックチューブに取り、ボルテックスミキサーで攪拌しながら15%トリクロロ酢酸(TCA) 1.2 ml、続いてPBS 1.5 mlを加え、酸変性したカゼイン、乳清由来の高分子タンパク質を遠心除去(17000 x g、6min、4℃)した。回収した上清1.2ml に等量のPBS 1.2mlを添加したものの内2mlをあらかじめ100%メタノール2ml、HPLC用蒸留水(0.1%TFA含有)2mlで平衡化した固相抽出用カラム(Waters OASISTM HLB1cc (30mg))にアプライした。カラム中のTCAや非吸着物を蒸留水(0.1% TFA含有) 2ml、5% メタノール(0.1% TFA含有) 2mlで順次洗浄除去した後、50%アセトニトリル(0.1% TFA含有) 2mlにてCPP含有画分を溶出した。得られたCPP含有画分は遠心濃縮機により乾固した。なお、検量線サンプルも乳製品サンプルと同様の前処理を行った。
競合ELISA法は以下に述べる手順で行った。
前処理済みの乳製品サンプル及び検量線サンプルをPBS 0.5mlに溶解し検体原液とした。全ての検体原液をPBSでさらに5倍希釈し、2%BSA/PBSで希釈したmAb 1A5(2μg/ml)と1:1 (50μl:50μl)の量比でU底96ウエルプレート(FALCON #351177)中でプレインキュベーション(37℃、1.5時間)した。測定用96ウエルプレート(Nunc MaxiSorp)は、PBSに溶解したCPPIII(50μg/ml)を100μl/wellで37℃、2時間以上コーティングした後、1%BSA/PBSで37℃1時間ブロッキングした。ブロッキング済みの測定用プレートにプレインキュベーションした検体とmAb 1A5の反応物を50μl/well移し、37℃で1時間反応した。続いて、競合未反応物を洗浄液により除去し、プレート上にコートしたCPPIII中のβ-CPPと結合したmAb 1A5を検出するために、1%BSA/PBSで6000倍に希釈した2次抗体(ペルオキシダーゼ標識ウサギ抗マウス免疫グロブリン抗体(Rockland社))を100μl/well加え、37℃で1時間インキュベーションした。次に、未反応の2次抗体を洗浄液により除去した後、基質発色液 (DAKOTM TMB+SUBSTRATE-CHROMOGEN)を100μl/well分注した。室温で5分間呈色反応を行った後、1Nの硫酸水溶液を100μl/well添加して反応を停止し、プレートリーダを用いて吸光度 (OD 450 nm)を測定した。検量線サンプルの各CPP-ACP濃度と対応する吸光度をそれぞれx、y軸にプロットして作成した検量線より乳製品サンプル中のCPP-ACP量を算出した。検量線は測定毎に作成し、乳製品サンプルと同一のプレートで測定したデータを使用した。
CPP-ACP濃度を0、1、2及び3mg/mlに調製した検量線サンプルについて、前処理、競合ELISA法を実施して得られた検量線を図7に示した。検量線の近似関数としては1次式を当てはめた。
次に検量線から得られた近似関数に乳製品サンプル(n =3)の吸光度を当てはめ、CPP-ACP配合量を求めた(表3)。
[Example 5] Measurement of CPP-ACP content blended in dairy product (trial product) 1 g of CPP-ACP base material (Cadbury Schweppes) used for trial production as a calibration curve sample was weighed, and 100 ml volumetric flask with distilled water After being dissolved in (10 mg / ml), 2.5 ml was dispensed into a tube and dried by a centrifugal concentrator (25 mg / tube). Subsequently, 5 ml of milk was added to 25 mg of CPP-ACP drug substance and dissolved sufficiently (5 mg / ml), and then serially diluted with milk so that the final concentrations were 1, 2 and 3 mg / ml. The concentration of CPP-ACP in milk without CPP-ACP was 0 mg / ml.
The sample preparation method was performed according to the procedure described below.
Take 0.3 ml of dairy sample in a plastic tube, add 1.2 ml of 15% trichloroacetic acid (TCA) and then 1.5 ml of PBS while stirring with a vortex mixer, and centrifuge to remove acid-denatured casein and high molecular weight protein from whey (17000 xg, 6 min, 4 ° C). A 1.2 ml solid phase extraction column (Waters OASIS TM ) equilibrated with 2 ml of 100% methanol and 2 ml of HPLC distilled water (containing 0.1% TFA) was added to 1.2 ml of the collected supernatant and 1.2 ml of an equal volume of PBS. HLB1cc (30 mg)) was applied. TCA and non-adsorbed materials in the column were washed and removed with 2 ml of distilled water (containing 0.1% TFA) and 2 ml of 5% methanol (containing 0.1% TFA), and then CPP contained in 2 ml of 50% acetonitrile (containing 0.1% TFA). The fraction was eluted. The obtained CPP-containing fraction was dried using a centrifugal concentrator. The calibration curve sample was also pretreated in the same manner as the dairy product sample.
The competitive ELISA method was performed according to the procedure described below.
A pretreated dairy product sample and a calibration curve sample were dissolved in 0.5 ml of PBS to obtain a specimen stock solution. All specimen stock solutions were further diluted 5-fold with PBS, and a U-bottom 96-well plate (FALCON # 351177) with a ratio of 1: 1 (50 μl: 50 μl) to mAb 1A5 (2 μg / ml) diluted with 2% BSA / PBS. ) Was preincubated (37 ° C., 1.5 hours). A 96-well plate (Nunc MaxiSorp) for measurement was coated with CPPIII (50 μg / ml) dissolved in PBS at 100 μl / well at 37 ° C. for 2 hours or more, and then blocked with 1% BSA / PBS at 37 ° C. for 1 hour. The preincubated specimen and mAb 1A5 reaction product were transferred to a blocking measurement plate at 50 μl / well and reacted at 37 ° C. for 1 hour. Subsequently, the unreacted unreacted product was removed with a washing solution, and a secondary antibody diluted 6000 times with 1% BSA / PBS to detect mAb 1A5 bound to β-CPP in CPPIII coated on the plate ( 100 μl / well of peroxidase-labeled rabbit anti-mouse immunoglobulin antibody (Rockland) was added and incubated at 37 ° C. for 1 hour. Next, the unreacted secondary antibody was removed with a washing solution, and then a substrate coloring solution (DAKO ™ TMB + SUBSTRATE-CHROMOGEN) was dispensed at 100 μl / well. After a color reaction at room temperature for 5 minutes, 100 μl / well of 1N sulfuric acid aqueous solution was added to stop the reaction, and absorbance (
FIG. 7 shows calibration curves obtained by performing pretreatment and competitive ELISA for calibration curve samples prepared with CPP-ACP concentrations of 0, 1, 2, and 3 mg / ml. A linear equation was applied as an approximate function of the calibration curve.
Next, the absorbance of the dairy sample (n = 3) was applied to the approximate function obtained from the calibration curve to obtain the CPP-ACP blending amount (Table 3).
[実施例6] 単位CPP-ACP量に含まれるβ-CPP含量の測定
0〜10 μg/ml濃度に調製したβ-CPP測定用検量線サンプルについて、競合ELISA法を実施して得られた検量線を図8に示した。検量線の近似関数としては指数曲線を当てはめた。
次に検量線から得られた近似関数にCPP-ACPの各濃度に対応した吸光度を当てはめ、β-CPPへの換算値を求めると共に、単位CPP-ACP量に含まれるβ-CPP含量を求めた(表4)。
[Example 6] Measurement of β-CPP content contained in unit CPP-ACP amount
FIG. 8 shows a calibration curve obtained by performing the competitive ELISA method for a calibration curve sample for β-CPP measurement prepared at a concentration of 0 to 10 μg / ml. An exponential curve was fitted as an approximate function of the calibration curve.
Next, the absorbance corresponding to each concentration of CPP-ACP was applied to the approximate function obtained from the calibration curve to obtain the converted value to β-CPP, and the β-CPP content contained in the unit CPP-ACP amount was obtained. (Table 4).
表4よりCPP-ACP原体1mg中のβ-CPP含量は0.109mgであった。
乳製品サンプル中にはCPP-ACPが2.67mg/ml含まれており(実施例5より)、
CPP-ACP 1mg中のβ-CPP含量として0.1090mgであることから(実施例6より)、乳製品サンプル中に配合されたβ-CPP量は0.29(=2.67 x 0.109)mg/mlとなる。
From Table 4, the β-CPP content in 1 mg of CPP-ACP drug substance was 0.109 mg.
The dairy sample contains 2.67 mg / ml of CPP-ACP (from Example 5),
Since the β-CPP content in 1 mg of CPP-ACP is 0.1090 mg (from Example 6), the amount of β-CPP compounded in the dairy product sample is 0.29 (= 2.67 × 0.109) mg / ml.
本発明は、特殊な機器や高価な装置を使わないで、簡便にかつ高い精度と特異性を持ってCPP及びCPP複合体を測定できる。特に乳製品のような配合するCPP及びCPP複合体と類似する物質が多量に存在する溶液中に含まれるCPP、CPP複合体さらにβ-CPP量の測定に適している。用途として、CPP及びCPP複合体素材を食品或いは医薬品に配合した製品の規格・品質管理へ適用できる。さらには、体内動態、薬効薬理試験など基礎研究の分析ツールとしても有用である。 The present invention can measure CPP and CPP complex easily and with high accuracy and specificity without using special equipment or expensive equipment. In particular, it is suitable for the measurement of the amount of CPP, CPP complex and β-CPP contained in a solution containing a large amount of substances similar to CPP and CPP complex to be blended such as dairy products. As a use, it can be applied to the standard and quality control of products in which CPP and CPP composite materials are blended with food or medicine. Furthermore, it is useful as an analytical tool for basic research such as pharmacokinetics and pharmacological studies.
Claims (3)
(1)試料に酸を加え、タンパク質を変性・除去する工程
(2)固相抽出により、酸を除去する工程
(3)固相から溶出した精製試料を配列番号:1記載のリン酸化ペプチドに対するモノクローナル抗体(mAb 1A5)を用いて免疫学的測定を行う。 The quantification method according to claim 1, which comprises an immunological assay comprising the following steps.
(1) Step of adding acid to sample and denaturing / removing protein (2) Step of removing acid by solid phase extraction (3) Purified sample eluted from solid phase for phosphorylated peptide of SEQ ID NO: 1 Immunological measurements are performed using a monoclonal antibody (mAb 1A5).
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006001851A JP4877920B2 (en) | 2006-01-06 | 2006-01-06 | Specific quantification method of β-casein phosphopeptide (β-CPP) using immunological technique |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006001851A JP4877920B2 (en) | 2006-01-06 | 2006-01-06 | Specific quantification method of β-casein phosphopeptide (β-CPP) using immunological technique |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007183187A true JP2007183187A (en) | 2007-07-19 |
JP4877920B2 JP4877920B2 (en) | 2012-02-15 |
Family
ID=38339412
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006001851A Active JP4877920B2 (en) | 2006-01-06 | 2006-01-06 | Specific quantification method of β-casein phosphopeptide (β-CPP) using immunological technique |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4877920B2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9261913B2 (en) | 2010-03-30 | 2016-02-16 | Hewlett-Packard Development Company, L.P. | Image of a keyboard |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05246882A (en) * | 1992-02-03 | 1993-09-24 | Snow Brand Milk Prod Co Ltd | Inhibitor of gastric acid secretion, antiulcer agent and food and drink comprising proteose peptone component 8f as active ingredient |
JPH11310599A (en) * | 1998-02-27 | 1999-11-09 | Snow Brand Milk Prod Co Ltd | Polymer type calcium/phosphopeptide complex |
JP2001153868A (en) * | 1999-11-26 | 2001-06-08 | Meiji Milk Prod Co Ltd | Immunoassay of assaying casein phosphopetide(cpp) |
-
2006
- 2006-01-06 JP JP2006001851A patent/JP4877920B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05246882A (en) * | 1992-02-03 | 1993-09-24 | Snow Brand Milk Prod Co Ltd | Inhibitor of gastric acid secretion, antiulcer agent and food and drink comprising proteose peptone component 8f as active ingredient |
JPH11310599A (en) * | 1998-02-27 | 1999-11-09 | Snow Brand Milk Prod Co Ltd | Polymer type calcium/phosphopeptide complex |
JP2001153868A (en) * | 1999-11-26 | 2001-06-08 | Meiji Milk Prod Co Ltd | Immunoassay of assaying casein phosphopetide(cpp) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9261913B2 (en) | 2010-03-30 | 2016-02-16 | Hewlett-Packard Development Company, L.P. | Image of a keyboard |
Also Published As
Publication number | Publication date |
---|---|
JP4877920B2 (en) | 2012-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Cui et al. | In vitro digestion profile and calcium absorption studies of a sea cucumber ovum derived heptapeptide–calcium complex | |
Ferrer et al. | High-performance liquid chromatographic determination of furfural compounds in infant formulas: Changes during heat treatment and storage | |
Ulrichs et al. | Determination of heat-induced changes in the protein secondary structure of reconstituted livetins (water-soluble proteins from hen’s egg yolk) by FTIR | |
Sawyer | β-Lactoglobulin | |
Butler et al. | The Escherichia coli multidrug transporter EmrE is a dimer in the detergent-solubilised state | |
Indyk et al. | Determination of lactoferrin in bovine milk, colostrum and infant formulas by optical biosensor analysis | |
CN102590413B (en) | Quantitative detection method for bovine alpha-lactalbumin | |
Li et al. | Quantitative proteomic analysis of milk fat globule membrane (MFGM) proteins from donkey colostrum and mature milk | |
Tukiran et al. | Determination of porcine gelatin in edible bird's nest by competitive indirect ELISA based on anti-peptide polyclonal antibody | |
Spaenij-Dekking et al. | A novel and sensitive method for the detection of T cell stimulatory epitopes of α/β-and γ-gliadin | |
Murray et al. | Peptidomic screening of bitter and nonbitter casein hydrolysate fractions for insulinogenic peptides | |
Liao et al. | Proteomic characterization of specific minor proteins in the human milk casein fraction | |
Bernard et al. | Molecular basis of IgE cross-reactivity between human β-casein and bovine β-casein, a major allergen of milk | |
Fang et al. | Self-assembled β-lactoglobulin–oleic acid and β-lactoglobulin–linoleic acid complexes with antitumor activities | |
Hellwig et al. | Release of pyrraline in absorbable peptides during simulated digestion of casein glycated by 3-deoxyglucosone | |
Indyk et al. | An optical biosensor-based immunoassay for the determination of bovine serum albumin in milk and milk products | |
Nissen et al. | Expanding the bovine milk proteome through extensive fractionation | |
CN104991077B (en) | Troponin I competes turbidimetry detection kit | |
Luo et al. | Deciphering calcium-binding behaviors of casein phosphopeptides by experimental approaches and molecular simulation | |
Liu et al. | Isolation and identification of zinc‐chelating peptides from sea cucumber (Stichopus japonicus) protein hydrolysate | |
Saliha et al. | Separation and characterization of major milk proteins from Algerian Dromedary (Camelus dromedarius). | |
Madsen et al. | The impact of structural integrity and route of administration on the antibody specificity against three cow’s milk allergens-a study in Brown Norway rats | |
Nielsen et al. | Development and application of a multiple reaction monitoring mass spectrometry method for absolute quantification of lysinoalanine and lanthionine in dairy products | |
Seeley et al. | Reduction of non-specific binding in Ga (III) immobilized metal affinity chromatography for phosphopeptides by using endoproteinase glu-C as the digestive enzyme | |
Lu et al. | Effects of calcium-binding peptide from tilapia scale protein hydrolysates on calcium absorption in Caco-2 cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080805 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20100901 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100914 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20101025 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101111 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110201 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110316 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110614 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20111124 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20111124 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4877920 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20141209 Year of fee payment: 3 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |